Education
About Us
Working with TipRanks
Follow Us
Skye Bioscience (SKYE)
NASDAQ:SKYE
Total Valuation
Skye Bioscience has a market cap or net worth of $26.75M. The enterprise value is $120.90M.
Market Cap$26.75M
Enterprise Value$120.90M
Share Statistics
Skye Bioscience has 32,057,460 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding32,057,460
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Skye Bioscience’s return on equity (ROE) is -0.39 and return on invested capital (ROIC) is -53.12%.
Return on Equity (ROE)-0.39
Return on Assets (ROA)-0.37
Return on Invested Capital (ROIC)-53.12%
Return on Capital Employed (ROCE)-0.53
Revenue Per Employee0.00
Profits Per Employee-1.66M
Employee Count16
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Skye Bioscience is ―. Skye Bioscience’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio1.52
Price to Fair Value1.52
Price to FCF-3.85
Price to Operating Cash Flow-1.52
PEG Ratio0.04
Income Statement
In the last 12 months, Skye Bioscience had revenue of 0.00 and earned -26.57M in profits. Earnings per share was -0.73.
Revenue0.00
Gross Profit0.00
Operating Income-30.19M
Pretax Income-26.56M
Net Income-26.57M
EBITDA-25.29M
Earnings Per Share (EPS)-0.73
Cash Flow
In the last 12 months, operating cash flow was -9.22B and capital expenditures -6.36M, giving a free cash flow of -9.22B billion.
Operating Cash Flow-9.22B
Free Cash Flow-9.22B
Free Cash Flow per Share-287.74
Dividends & Yields
Skye Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.22
52-Week Price Change-66.26%
50-Day Moving Average1.30
200-Day Moving Average2.46
Relative Strength Index (RSI)27.87
Average Volume (3m)344.35K
Important Dates
Skye Bioscience upcoming earnings date is Mar 19, 2026, After Close (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 19, 2026
Ex-Dividend Date―
Financial Position
Skye Bioscience as a current ratio of 16.32, with Debt / Equity ratio of 0.84%
Current Ratio16.32
Quick Ratio16.32
Debt to Market Cap<0.01
Net Debt to EBITDA2.66
Interest Coverage Ratio-48.61
Taxes
In the past 12 months, Skye Bioscience has paid 10.07K in taxes.
Income Tax10.07K
Effective Tax Rate>-0.01
Enterprise Valuation
Skye Bioscience EV to EBITDA ratio is -1.38, with an EV/FCF ratio of -1.32.
EV to Sales0.00
EV to EBITDA-1.38
EV to Free Cash Flow-1.32
EV to Operating Cash Flow-1.40
Balance Sheet
Skye Bioscience has $35.31M in cash and marketable securities with $321.85K in debt, giving a net cash position of $34.99M billion.
Cash & Marketable Securities$35.31M
Total Debt$321.85K
Net Cash$34.99M
Net Cash Per Share$1.09
Tangible Book Value Per Share$1.87
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Skye Bioscience is $9.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$9.80
Price Target Upside1080.72% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast-53.18%